View all news

Nassau University Medical Center in New York Adds Noninvasive Patient Monitoring Capabilities With Masimo Pulse Oximetry & Pulse CO-Oximetry(TM) Conversion

New Noninvasive Medical Technology Advancements Improve Patient Monitoring, Safety, and Quality

IRVINE, Calif., April 14, 2010 /PRNewswire via COMTEX/ --Nassau University Medical Center (NUMC) and Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low Perfusion pulse oximetry, today jointly announced completion of NUMC's system-wide conversion to Masimo oximetry technologies. The conversion ensures that NUMC patients will be monitored noninvasively using the most technologically and clinically-advanced pulse oximetry and Pulse CO-Oximetry technologies available--providing real-time results for vital measurements that help clinicians to more rapidly assess, diagnose, and treat patients.

"Converting to Masimo has greatly advanced our noninvasive patient monitoring capabilities and we've been particularly happy with the time it saves us during critical trauma cases," said Paul Weinberg, M.D., Chairman of Anesthesia at Nassau University Medical Center. "With Masimo noninvasive hemoglobin, we see the trend much quicker so we know where the patient's blood volume is heading and can better anticipate what needs to be done. It's unique to have immediate access to this level of clinical detail with the ability to track blood levels so accurately."

The system-wide conversion standardizes all of NUMC's sites of care, including over 530 hospital beds, to Masimo technology, which involved upgrading the hospital's multiparameter patient monitors, pulse oximeters, and sensors. Masimo offers the only upgradeable pulse oximetry technology platform--Masimo Rainbow SET Pulse CO-Oximetry--that allows hospitals to add breakthrough noninvasive blood constituent measurement capabilities that previously required invasive procedures. The ability to continuously and noninvasively measure total hemoglobin (SpHb(R)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), PVI(R), and acoustic respiration rate (RRa(TM)), in addition to Masimo SET 'gold standard' Measure-Through Motion and Low Perfusion oxyhemoglobin (SpO2), perfusion index (PI), and pulse rate (PR) measurements enables monitoring of multiple physiological parameters simultaneously--to help clinicians detect life-threatening conditions and help guide treatment options.

Masimo Founder and CEO, Joe E. Kiani, said, "Nassau University Medical Center's conversion to Masimo's oximetry technology provides clinicians with the patient monitoring tools they need to increase early detection of physiological deterioration and improve safety. The noninvasive and continuous measurements provided by Masimo Rainbow SET Pulse CO-Oximetry arms clinicians with new visibility into the physiology and underlying condition of their patients--helping to expand their clinical capabilities."

About the NuHealth System

NuHealth is a Long Island health care organization delivering essential medical care and disease and lifestyle management to everyone at every stage of life. Also known as Nassau Health Care Corporation, NuHealth is a public benefit corporation managing the operations of Nassau University Medical Center, A. Holly Patterson Extended Care and a network of Family Health Centers that bring primary and specialty care out into the community. By emphasizing wellness, cultural sensitivity and collaborative efforts with the North Shore-LIJ Health System, NuHealth is working to make good care more affordable and easier to access. For more information about NuHealth or its Centers of Care, visit

About Masimo

Masimo (Nasdaq: MASI) develops innovative monitoring technologies that significantly improve patient care--helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET(R), which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET(R) Pulse CO-Oximetry(TM), allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), and PVI(R), in addition to SpO2, pulse rate, and perfusion index (PI). In 2009, Masimo introduced Masimo Rainbow SET(R) Acoustic Monitoring(TM), the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa). Masimo's Rainbow platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at

Forward Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our belief that Masimo SET and Masimo Rainbow SET oximetry technologies will provide sufficient sensitivity and specificity to accurately detect physiological abnormalities and potentially life-threatening conditions in real-time for all patients, risks related to our belief that Masimo SET and Rainbow SET measurements will help clinicians guide treatment options, risks related to our assumptions regarding the repeatability of clinical results, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Media Contacts:
Dana Banks Masimo Corporation
(949) 297-7348
Shelley Lotenberg
Nassau University Medical Center
(516) 572-6055

Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, RRa, Radical-7, Rad-87, Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.


Multimedia Files:

Categories: Press Releases
View all news